Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02831816
Other study ID # ZX-ZP-0074 / 150316-103
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 3, 2016
Est. completion date August 3, 2017

Study information

Verified date June 2021
Source Zurex Pharma, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the study is to demonstrate the antimicrobial efficacy of the ZP Preoperative Prep on skin flora of the abdomen and inguinal regions of human subjects.


Recruitment information / eligibility

Status Completed
Enrollment 640
Est. completion date August 3, 2017
Est. primary completion date August 3, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects of any race. - Subjects in good health. - Minimum skin flora baseline requirements on abdomen and groin. - Skin free of tattoos, dermatoses, abrasions, cuts, lesions, or other skin disorder near or on the applicable test area. Exclusion Criteria: - Topical or systemic antimicrobial exposure within 14 days prior to screening and treatment days, including antibiotics. - Subjects with a history of skin sensitivity, skin allergies, or skin cancer. - Subjects who are pregnant, attempting pregnancy, or nursing.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ZuraPrep
Apply topically.
ChloraPrep
Apply topically.
ZP Vehicle
Apply topically.

Locations

Country Name City State
United States BioScience Laboratories, Inc. Bozeman Montana

Sponsors (1)

Lead Sponsor Collaborator
Zurex Pharma, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bacterial Reduction A a 3-log per cm2 bacterial reduction on the inguinal region is considered a success. 10 minutes post product application
Primary Bacterial Reduction - Abdomen A 2-log per cm2 bacterial reduction on the abdomen region is considered a success. 10 minutes post product application
See also
  Status Clinical Trial Phase
Completed NCT03681990 - In Vivo Preoperative Skin Preparation Efficacy Study Within a Defined Product Coverage Area Phase 2
Completed NCT04756154 - Efficacy Study of Patient Preoperative Preps In-vivo Phase 3
Completed NCT02831998 - In-vivo Efficacy of Patient Preoperative Prep Phase 3
Completed NCT03331263 - Single Dose CHG Pharmacokinetic Study Phase 1
Completed NCT03782103 - In-vivo Efficacy of Patient Preoperative Prep, ZuraPrep (ZP) Phase 3